SEP 15, 2020 9:00 AM PDT

Turmeric Better than Placebo for Osteoarthritis Pain

WRITTEN BY: Annie Lennon

Researchers from the University of Tasmania in Australia have found that an extract from turmeric is more effective than placebo treatments at reducing knee pain from osteoarthritis.

For the study, the researchers recruited 70 participants with symptomatic knee osteoarthritis. Each participant was then instructed to either take two capsules of turmeric per day or a placebo over a 12-week period. Changes in pain and knee effusion-synovitis volume (when excess fluid accumulates around the knee joint) were assessed via both a standardized questionnaire and an MRI scan over the study period. 

The researchers also measured changes in cartilage composition, usage of pain medication, quality of life, physical performance, and incidence of adverse events. 

In the end, the researchers found that patients who took turmeric supplements tended to experience less pain than those in the placebo group. Importantly, they also noted no adverse events in this group, and that they consumed fewer pain medications than those in the placebo group.

The researchers, however, found no difference in the structural aspects of knee osteoarthritis between the groups. This suggests that, while turmeric may relieve certain symptoms of pain, it is no cure for the condition. 

Regardless, the results point towards the possibility of turmeric being used as a dietary supplement to manage pain better than existing treatments such as acetaminophen and non-steroidal anti-inflammatory drugs, often associated with adverse effects. 

Although promising, the researchers caution that further examination is needed to certify turmeric's pain-relieving effects. In particular, they say that the study's sample size was somewhat small, and the short duration of the follow-up, alongside all patients being treated in the same research center, makes the results less conclusive. As a next step, the researchers thus recommend further studies to have larger sample sizes across multiple centers with longer follow-up durations. 

 

Sources: Neuroscience NewsAnnals of Internal Medicine

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 14, 2020
Immunology
Self-Healing Microcapsules Make Promising Leukemia Vaccines
OCT 14, 2020
Self-Healing Microcapsules Make Promising Leukemia Vaccines
Leukemia is a cancer affecting tissues in the body that produce blood cells, including the bone marrow and the lymphatic ...
OCT 23, 2020
Drug Discovery & Development
FDA Gives Full Approval to Remdesivir to Treat COVID-19
OCT 23, 2020
FDA Gives Full Approval to Remdesivir to Treat COVID-19
The US Food and Drug Administration (FDA) has approved antiviral drug Remdesivir, sold under the name ‘Velkury&rsq ...
OCT 11, 2020
Drug Discovery & Development
Treating Connective Tissue Disorders
OCT 11, 2020
Treating Connective Tissue Disorders
Collaborative research efforts are geared to improving disease that affects connective tissues via innovative drug deliv ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 02, 2020
Drug Discovery & Development
Potential Therapy for Alzheimer Disease
NOV 02, 2020
Potential Therapy for Alzheimer Disease
A main characteristic of Alzheimer disease is an aggregate of a protein (peptide) clump in the brain leading to memory l ...
NOV 23, 2020
Drug Discovery & Development
Therapeutically Active Ion-Channels
NOV 23, 2020
Therapeutically Active Ion-Channels
Therapeutically relevant ion channels have inspired researchers to look into drugs that can regulate their activity. Ion ...
Loading Comments...